{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:43:57Z","timestamp":1773157437540,"version":"3.50.1"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Mehrere Spezies wurden neu klassifiziert, darunter klinisch relevante Spezies wie C. glabrata (Nakaseomyces glabratus), C. krusei (Pichia kudriavzevii) und C. auris (Candidozyma auris). Die neue Leitlinie empfiehlt, f\u00fcr die n\u00e4chsten Jahre in Befunden beide Bezeichnungen zu nennen.<\/jats:p>\n                  <jats:p>C. auris zeigt eine hohe Umweltstabilit\u00e4t, ist h\u00e4ufig multiresistent gegen\u00fcber Antimykotika und ist weltweit Ausl\u00f6ser zahlreicher Ausbr\u00fcche. Der Nachweis aus sterilen Materialien ist in Deutschland seit 2023 meldepflichtig. Ein Zuwachs an resistenten C.-auris-Isolaten ist in Deutschland zu erwarten.<\/jats:p>\n                  <jats:p>In Berlin wurde zwischen 2018 und 2022 ein Ausbruch mit einem Fluconazol-resistenten C.-parapsilosis-Stamm nachgewiesen. Eine Verwandtschaft der Isolate wurde molekulargenetisch nachgewiesen.<\/jats:p>\n                  <jats:p>Bei C. tropicalis und C. glabrata nehmen Resistenzen gegen die h\u00e4ufig eingesetzten Azol-Antimykotika weltweit zu. Bei C. glabrata werden dar\u00fcber hinaus zunehmende Resistenzen gegen die Erstlinientherapie mit Echinocandinen beobachtet, wodurch die Therapiem\u00f6glichkeiten erheblich beeintr\u00e4chtigt werden.<\/jats:p>\n                  <jats:p>F\u00fcr C. auris hat EUCAST erstmals Breakpoints f\u00fcr die Echinocandine Anidulafungin und Micafungin sowie f\u00fcr Amphotericin B eingef\u00fchrt. F\u00fcr Amphotericin B wurde die gesamte Wildtyp-Population als \u201eempf\u00e4nglich bei erh\u00f6hter Exposition \u201c (Susceptible, increased Exposure, I) eingestuft.<\/jats:p>\n                  <jats:p>Eine antimykotische Prophylaxe mittels Azol-Antimykotika wird bei Hochrisikopatienten oder bei Neutropenie empfohlen. Bei Vorliegen einer Azol-Resistenz kommen Echinocandine zum Einsatz.<\/jats:p>\n                  <jats:p>F\u00fcr die Erstlinientherapie der Candid\u00e4mie wird der Einsatz von Echinocandinen empfohlen. In der Klasse der Echinocandine wurde 2024 das neue Echinocandin Rezafungin zugelassen, welches nur einmal w\u00f6chentlich infundiert werden muss. Neue Substanzen wie Fosmanogepix und Ibrexafungerp bieten vielversprechende, neue Therapieoptionen zur Therapie von Candida-Infektionen und werden das Antimykotika-Portfolio zuk\u00fcnftig erweitern.<\/jats:p>","DOI":"10.1055\/a-2645-5607","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:30:25Z","timestamp":1773099025000},"page":"269-274","source":"Crossref","is-referenced-by-count":0,"title":["Neuerungen im Management von Candida-Infektionen"],"prefix":"10.1055","volume":"151","author":[{"given":"Susanne","family":"Fadlalla","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ram.2022.08.003","article-title":"Candida albicans the main opportunistic pathogenic fungus in humans","volume":"55","author":"IU Macias-Paz","year":"2023","journal-title":"Rev Argent Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11046-024-00871-0","article-title":"Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV","volume":"189","author":"S Wolfgruber","year":"2024","journal-title":"Mycopathologia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"P Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jinf.2023.08.001","article-title":"European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study","volume":"87","author":"MC Arendrup","year":"2023","journal-title":"J Infect"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"OA Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00937-24","article-title":"Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology","volume":"62","author":"S De Hoog","year":"2024","journal-title":"J Clin Microbiol"},{"key":"ref7","volume-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"World Health Organization","year":"2022"},{"key":"ref8","first-page":"2","article-title":"Zunahme von Candida auris in Deutschland im Jahr 2023","volume":"18","author":"Robert Koch-Institut","year":"2024","journal-title":"Epidemiol Bull"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.cmi.2025.04.003","article-title":"How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications","volume":"31","author":"KJG Da Silva","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.07.012","article-title":"Genomic reconstruction of an azole-resistant Candida parapsilosis outbreak and the creation of a multi-locus sequence typing scheme: a retrospective observational and genomic epidemiology study","volume":"6","author":"PJT Brassington","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1594226","article-title":"Research progress on the drug resistance mechanisms of Candida tropicalis and future solutions","volume":"16","author":"H Xiong","year":"2025","journal-title":"Front Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/antibiotics13090840","article-title":"Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest","volume":"13","author":"M Asadzadeh","year":"2024","journal-title":"Antibiotics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e01528","DOI":"10.1128\/jcm.01528-23","article-title":"Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance","volume":"62","author":"M Siopi","year":"2024","journal-title":"J Clin Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S1198","DOI":"10.1016\/j.cmi.2025.07.002","article-title":"How to interpret MICs of amphotericin B, echinocandins and flucytosine against Candida auris (Candidozyma auris) according to the newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints","volume":"11","author":"MC Arendrup","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"M Hoenigl","year":"2021","journal-title":"Drugs"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2645-5607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:30:30Z","timestamp":1773099030000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2645-5607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2645-5607","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}